Arena Updates Etrasimod Timelines, Introduces New Drug Candidate
Late-Stage S1P Modulator Data Due Later In 2021, Early In 2022
CEO Amit Munshi told the J.P. Morgan meeting the company will double the size of its clinical-stage cardiovascular disease pipeline with the addition of temanogrel.